2022
P766: CLINICAL OUTCOMES IN PATIENTS WITH HIGHER‐RISK MYELODYSPLASTIC SYNDROMES RECEIVING HYPOMETHYLATING AGENTS: A LARGE POPULATION‐BASED ANALYSIS
Zeidan A, Mearns E, Ng C, Shah A, Lamarre N, Yellow‐Duke A, Alrawashdh N, Yang B, Cheng W, Bui C, Svensson A. P766: CLINICAL OUTCOMES IN PATIENTS WITH HIGHER‐RISK MYELODYSPLASTIC SYNDROMES RECEIVING HYPOMETHYLATING AGENTS: A LARGE POPULATION‐BASED ANALYSIS. HemaSphere 2022, 6: 661-662. DOI: 10.1097/01.hs9.0000845948.33476.47.Peer-Reviewed Original ResearchP787: SABATOLIMAB (MBG453) COMBINATION TREATMENT REGIMENS FOR PATIENTS WITH HIGHER‐RISK MYELODYSPLASTIC SYNDROMES: THE MYELODYSPLASTIC SYNDROMES STUDIES IN THE STIMULUS IMMUNO‐MYELOID CLINICAL TRIAL PROGRAM
Zeidan A, Al‐Kali A, Borate U, Cluzeau T, DeZern A, Esteve J, Giagounidis A, Kobata K, Lyons R, Platzbecker U, Sallman D, Santini V, Sanz G, Sekeres M, Wei A, Xiao Z, Van Hoef M, Nourry‐Boulot C, Sadek I, Ma F, Iordan A, Sabo J, Garcia‐Manero G. P787: SABATOLIMAB (MBG453) COMBINATION TREATMENT REGIMENS FOR PATIENTS WITH HIGHER‐RISK MYELODYSPLASTIC SYNDROMES: THE MYELODYSPLASTIC SYNDROMES STUDIES IN THE STIMULUS IMMUNO‐MYELOID CLINICAL TRIAL PROGRAM. HemaSphere 2022, 6: 682-683. DOI: 10.1097/01.hs9.0000846032.37876.c9.Peer-Reviewed Original ResearchPB1923: PATIENT AND PHYSICIAN CHARACTERISTICS ASSOCIATED WITH HYPOMETHYLATING AGENT USE IN HIGHER‐RISK MYELODYSPLASTIC SYNDROMES
Zeidan A, Divino V, DeKoven M, Shah D, Wang E, Bey D, Salimi T, Epstein R. PB1923: PATIENT AND PHYSICIAN CHARACTERISTICS ASSOCIATED WITH HYPOMETHYLATING AGENT USE IN HIGHER‐RISK MYELODYSPLASTIC SYNDROMES. HemaSphere 2022, 6: 1802-1803. PMCID: PMC9431607, DOI: 10.1097/01.hs9.0000850544.77658.8d.Peer-Reviewed Original Research
2021
P53 Topic: AS08-Treatment/AS08g-Clinical trials - Phase II-III PHASE 3 VERONA STUDY ASSESSING THE SAFETY AND EFFICACY OF VENETOCLAX WITH AZACITIDINE IN PATIENTS WITH NEWLY DIAGNOSED HIGHER-RISK MYELODYSPLASTIC SYNDROMES
Zeidan A, Garcia J, Fenaux P, Platzbecker U, Miyazaki Y, Xiao Z, Zhou Y, Naqvi K, Kye S, Manero G. P53 Topic: AS08-Treatment/AS08g-Clinical trials - Phase II-III PHASE 3 VERONA STUDY ASSESSING THE SAFETY AND EFFICACY OF VENETOCLAX WITH AZACITIDINE IN PATIENTS WITH NEWLY DIAGNOSED HIGHER-RISK MYELODYSPLASTIC SYNDROMES. Leukemia Research 2021, 108: 106681.52. DOI: 10.1016/j.leukres.2021.106681.52.Peer-Reviewed Original ResearchP10 Topic: AS03-Health Economics & Outcome Research/AS03a-Cost of care HOSPITALIZATION AND EMERGENCY ROOM VISITS AMONG PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES BY HYPOMETHYLATING AGENT USE
Zeidan A, Joshi N, Kale H, Wang W, Corman S, Hill K, Salimi T, Epstein R. P10 Topic: AS03-Health Economics & Outcome Research/AS03a-Cost of care HOSPITALIZATION AND EMERGENCY ROOM VISITS AMONG PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES BY HYPOMETHYLATING AGENT USE. Leukemia Research 2021, 108: 106681.10. DOI: 10.1016/j.leukres.2021.106681.10.Peer-Reviewed Original Research